Skip to main content

Premium on Gland Pharma shares declines significantly in grey market ahead of listing

In fact the premium has consistently been falling since the announcement of price band for its IPO in first week of November.

The share price premium of Gland Pharma in the grey market has significantly fallen ahead of the listing of shares later this week, despite the market being flooded with FII money and being traded at record high levels.

Shares are available at a premium of just Rs 6-10 in the grey market compared to its IPO price of Rs 1,500 per share, people familiar with the primary market development told Moneycontrol.



In fact, the premium has been falling consistently since the announcement of price band for its IPO in the first week of November. It was trading at a premium of Rs 200 per share just before the declaration of IPO price band, but then the premium fell to around Rs 60-70 and after closing of IPO, it further fell to Rs 35-40.

The high valuations and tepid response from investors (barring QIBs) could be some of key reasons for a decline in grey market premium.

"Uncertainty and lacked confidence from investors as a fact that 74 percent of Gland Pharma is owned by Chinese drug firm Fosun Pharma hurt local demand. Anti-Chinese sentiment due to the border dispute may have played a role in the reticence shown by domestic investors. As far as valuations are concerned even that was bit rich when compared to large pharma players in India and surprisingly we have seen huge rallies in pharma stocks in the past year which now trends low interest in new pharma entries," Prashanth Tapse, AVP Research at Mehta Equities told Moneycontrol.

"On overall basis institutional participation was also subdued compared to some other recent IPOs which is getting reflected in lower grey demand and supply before listing. Hence only high-risk long-term investors may hold rest allotted investors we advise to exit on decent listing," he said.

The pharma sector itself, especially after COVID-19 crisis, witnessed stellar rally given the huge healthcare demand. Nifty Pharma index climbed 83 percent from its March 23's low point.

The company launched its IPO during November 9-11, which was subscribed only 2.06 times. Only qualified institutional buyers helped the issue get subscribed as their reserved portion witnessed subscription of 6.4 times, while the response from retail investors (24 percent) and non-institutional investors (51 percent) was largely muted.

Gland Pharma, which is owned by China's Fosun Pharma, is expected to debut on bourses on November 20. Eligible investors are likely to get shares in their accounts by November 19 after the finalisation of basis of allotment around November 17.

The company raised Rs 6,480 crore via public issue, the second largest IPO after SBI Cards and Payment Services (Rs 10,355 crore) in 2020.

The public issue had comprised a fresh issue of Rs 1,250 crore and an offer for sale of over 3.48 crore shares by promoter and other selling shareholders.

Gland Pharma will utilise net proceeds from its fresh issue for funding incremental working capital requirements, funding capital expenditure requirements and general corporate purposes, while the promoter and selling shareholders received offer for sale money.

Source- Moneycontrol.com

Comments

Post a Comment

Popular posts from this blog

Panacea Biotech shares hit 5% upper circuit after dengue vaccine completes phase I & II study

DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes, the company has said in an exchange filing. Panacea Biotech share price hit 5 percent upper circuit on the BSE on September 24 after the company completed phases I and II study of its dengue vaccine candidate DengiAIl. "Panacea Biotec Ltd. is delighted to announce the successful completion of its Phase I/II study to evaluate the safety and immunogenicity of its vaccine, DengiAll, a single-dose liveattenuated tetravalent vaccine," the company said in an exchange filing. Live-attenuated vaccines contain weakened bacteria or viruses that trigger an immune response but do not cause disease. The company said DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes. DengiAIl has been found to be safe and well-tolerated with no serious adverse effects, the company said. After a single-dose, more than 80 percent of the participants ...
Post a Comment
Read more

Brokerages place bets on Titan, see double-digit upside in the stock

Titan can get benefits from the strong market share in the jewellery and wrist watches segment, mainly driven by a wide range of product portfolio catering mainly to the premium and value-added designer jewellery segment. After three consecutive sessions of losses, shares of Titan Company rose over a percent in morning trade on BSE on September 23. The company was dealt a severe blow by COVID-19 as the pandemic triggered strict lockdowns completely battered the retail sector. In the calendar year so far, shares of this one of the largest, most efficient and profitable specialty retailer in India are 7 percent down. The company reported a net standalone loss of Rs 270 crore for the quarter ended June 2020 as the COVID-19 pandemic hit business. The loss was higher than a CNBC-TV18 poll estimate of Rs 175 crore. Standalone revenue during the quarter declined 62.3 percent year-on-year to Rs 1,862 crore compared to the corresponding period last fiscal. Light at the end ...
Post a Comment
Read more

Indigo Paints trades at over 55% premium in grey market after IPO price announcement

The grey market premium has increased significantly from Rs 400-500 on January 11 to Rs 840-850 on January 15. Indigo Paints, one of the fastest-growing paint companies in India, was trading at more than 50 percent premium over its higher issue price band of Rs 1,490 per share in the grey market after the announcement of IPO details. The premium in the grey market as of January 15 was at around Rs 840-850 per share, which means the grey market trading price stood at Rs 2,340-2,330 against the issue price of Rs 1,490, as per the data available on IPO Watch. The premium increased significantly from Rs 400-500 on January 11 to Rs 840-850 today. The grey market is an unofficial trading platform where shares get traded well before the allotment in an initial public offering and till the shares get listed on bourses. It generally estimates the expected listing price of a stock. "Currently Asian paints and Berger paints are trading at a PE of 111 and 148, respectively, while Indigo Paint...
Post a Comment
Read more